Navigation Links
Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
Date:9/20/2010

PRINCETON, N.J., Sept. 20 /PRNewswire/ -- Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.  

Through the first SBIR grant, Signum will develop anti-inflammatory agents to reduce chronic redness (erythema) associated with eczema, atopic dermatitis, and rosacea. Access to more effective therapies is of significant importance to a large patient population suffering from chronic skin disease. Signum's Signal Transduction Modulator (STM) technology has already demonstrated significant reduction of redness in a double-blinded placebo controlled clinical study.

A second SBIR grant was awarded to fund Signum's identification and development of multi-functional, safe, topical anti-acne therapeutics. Acne is the most common disorder of the human skin and affects up to 80% of individuals at some point in their lives. Signum's STM technology has shown potential to reduce both inflammation and infection associated with acne.  

"We are proud to be awarded additional grants by the NIH, further supporting our unique approach and scientific direction. Our objective continues to be development of our technology with the goal of improving quality of life for the large number of patients suffering from skin disease," stated Dr. Braham Shroot, Chief Executive Officer of Signum.  Signum has a history of successful grant funding including four NIH SBIRs for skin therapeutics totaling over $2.5M.  The company is currently in the second year of a two year $1.6 M phase II SBIR grant for the development of a rosacea therapeutic which will enter the clinic next year.  

About Signum Biosciences.

Signum Biosciences is a priv
'/>"/>

SOURCE Signum Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 Amgen (NASDAQ: ... two pivotal Phase 3, global, randomized, placebo-controlled trials ... treatment of secondary hyperparathyroidism (SHPT) in patients with ... met the primary endpoint, demonstrating that a greater ... achieved a greater than 30 percent reduction in ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... 2015 Zimmer Holdings, Inc. (NYSE and SIX: ... with buyers to divest in the United ... assets, Biomet Discovery® Elbow System assets and Cobalt™ bone ... Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... constructively with the Bureau of Competition Staff of the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... Reportlinker.com announces that a new market research ... Triple Analysis: Lung Cancer, Lymphoma ... This triple analysis ... both Lung Cancer and Lymphoma and by ...
... 23, 2011 Applied Medical today announced that it ... Covidien) on May 17, 2011 in the U.S. District ... a recently issued Applied Medical trocar seal patent by ... Action No. CV 11-4203 VBF (AJWx). The patent is ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... On Thursday, May 14, the Mesothelioma ... Dr. Evan Alley both of the University of ... series. The interview was part of the series ... Drs. Simone and Alley were interviewed by the ... they discussed the mesothelioma program at the University ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The iconic ... Jones, will be hosting a new segment on Medical ... aspects of medical malpractice in the health care field. ... 2014 thousands of medical malpractice suits were filed, roughly ... 50% were settled out of court, while the remaining ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2
... Drought Tolerance, DES MOINES, Iowa, Feb. 4 ... today for a three-day project review,meeting focused on ... DD ) business Pioneer-Hi-Bred, the intent of ... and private organizations in order to,help increase farm ...
... The Beryl Companies announced today the,appointment ... president of,marketing communications. In this role, she ... branding initiatives, working closely,with sales, customer relations ... extensive background in marketing communications,research and operations ...
... by more than 78% , , MONDAY, Feb. 4 (HealthDay News) ... down, a new study shows it may also ease the ... simple sugar-and-water solution will also ease parents, fears and boost ... parents to get their children vaccinated," said study author Linda ...
... - Advocacy Group Urges Russian President Vladimir Putin to Adopt a ... ... The Movement Against Cancer, a cancer,patient advocacy group in Russia, ... inadequate access for cancer,patients in Russia to innovative and effective treatments, ...
... Calif., Feb. 4 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... announced that Jerry McMahon, Ph.D., chairman and CEO,will ... Investor Conference 2008 on,Monday, February 11, at 11:45 ... Dr. McMahon will provide a corporate overview, ...
... Medco Health,Solutions, Inc. (NYSE: MHS ) plans ... a press release before the market opens,on Tuesday, Feb. ... a conference call to review,the financial results, outlook and ... the live conference call via telephone:, Dial in: ...
Cached Medicine News:Health News:DuPont Hosts Meeting of Leading Plant Scientists to Improve World Agricultural Productivity 2Health News:Sugar Water Eases Pain of Infant Vaccinations 2Health News:Sugar Water Eases Pain of Infant Vaccinations 3Health News:Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia 2Health News:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Health News:Medco Announces Date for Fourth-Quarter and Full-Year 2007 Financial Results 2
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: